Keratoacanthoma
☆ I 2022 Stiftung Warentest-resultaterne fra Tyskland var forbrugernes tilfredshed med ModelDerm kun lidt lavere end med betalte telemedicinske konsultationer.
Typisk Keratoacanthoma
References
Keratoacanthoma (KA) er en hyppig hudtumor kendt for sin hurtige vækst og potentiale til at regrediere af sig selv. Det forekommer typisk hos ældre, lyshudede mænd med en historie med solskader. Mens kirurgisk fjernelse ved hjælp af excision eller Mohs mikrografisk kirurgi er den sædvanlige behandling, er der forskellige andre terapimuligheder tilgængelige.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) er en lavgradig tumor, der starter i visse kirtler i huden og ligner squamous cell carcinoma (SCC) under et mikroskop. Der er løbende debat om, hvorvidt KA skal klassificeres som en form for invasiv SCC.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) er den næsthyppigste form for kræft hos mennesker, især blandt ældre personer. Kirurgi bruges typisk til at behandle cSCC, men for nogle patienter, der ikke kan opereres eller vælger ikke at gøre det, kan andre muligheder såsom intralæsionale behandlinger overvejes. Traditionelle intralæsionelle behandlinger (methotrexate or 5-fluorouracil) er blevet brugt, men der er løbende forskning i nye tilgange som intralæsional immunterapi og onkolytisk viroterapi. Heri vil vi se på forskellige intralæsionale behandlinger for cSCC, lige fra klassiske metoder til banebrydende strategier.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Under mikroskopet ligner keratoacanthoma meget pladecellecarcinom. Mens nogle patologer klassificerer keratoacanthoma som en særskilt enhed og ikke en malignitet, udvikler omkring 6 % af de kliniske og histologiske keratoacanthoma sig til invasive og aggressive pladecellekræft.
○ Diagnose og behandling
#Dermoscopy
#Skin biopsy